We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Altered Ratios of p53 Isoforms Predict Response of Breast Tumors to Chemotherapy

By LabMedica International staff writers
Posted on 24 Nov 2022

Alterations in the distribution of p53 isoforms are predictive of the likelihood that a breast tumor will respond to treatment with the chemotherapeutic drug doxorubicin. More...

The regulatory protein p53 is often mutated in human cancers. In vertebrates, the p53 protein complex is vital for prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation.

Investigators at the Hunter Medical Research Institute (New Lambton Heights, Australia) have shown in previous studies that p53 isoform expression was altered in breast cancer and related to prognosis. In particular, a high delta40p53:p53alpha ratio was associated with worse disease-free survival.

In the current study, the influence of altered delta40p53 and p53alpha levels on the response to standard of care DNA-damaging agents used in breast cancer treatment was evaluated.

Results revealed that a high delta40p53:p53alpha ratio caused cells to respond differently to doxorubicin and cisplatin treatments. Delta40p53 overexpression significantly impaired the cells’ sensitivity to doxorubicin through reducing apoptosis and DNA damage, whereas inhibition of delta40p53 had the opposite effect. Further, a high delta40p53:p53alpha ratio inhibited the differential expression of several genes following doxorubicin and promoted DNA repair.

Overall, these results suggested that the response of breast cancer cells to standard of care DNA-damaging therapies was dependent on the expression of p53 isoforms, which may contribute to outcomes in breast cancer.

Senior author Dr. Kelly Avery-Kiejda, associate professor of biomedical sciences and pharmacy at he Hunter Medical Research Institute, said, “One in eight women in Australia develop breast cancer and while there is a 92% survival rate, this does not take into account secondary cancers or metastasis, which are essentially incurable. If we can identify biomarkers that predict how well a patient will respond to certain therapies, we can then target the available therapies more effectively.”

The findings were published in the October 28, 2022, online edition of the journal Cell Death & Disease.

Related Links:
Hunter Medical Research Institute 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.